GILD
New target, same bullish vibe
Gilead Sciences got a fresh glow-up from Cantor Fitzgerald, which lifted its price target to $155 from $115 and kept the stock at Overweight. In analyst-speak, that’s basically: “We still like the story, and we think the market is underappreciating it.”
Why you should care
This kind of move matters because price-target hikes can help reset expectations — and sometimes the whole mood music around a stock. For Gilead, that’s especially relevant right now with investors already obsessing over its HIV pipeline, commercial traction, and the latest round of deal and regulatory headlines.
The bigger picture
Gilead isn’t exactly flying under the radar. When Wall Street starts raising targets while the company is also making news on acquisitions and product growth, it can reinforce the idea that this isn’t just a sleepy pharma laggard — it’s a company with multiple catalysts trying to stack up at once.
- Higher target = analysts see more upside
- Overweight rating = Cantor still prefers the stock
- Comes amid a busy stretch of Gilead news, which can keep shares in the spotlight
Big picture: this won’t single-handedly launch the stock into orbit, but it does add another brick to the bullish wall.